First-episode psychosis questions are a Step 2 staple because they test the whole arc of care in one vignette: confirm the diagnosis, choose the right drug, and — the part students most often drop — keep treating after the patient improves. If you're working out how to treat first-episode psychosis for USMLE Step 2, this is the answer pattern that matches how the exam writes its keys.

Step 1 of the answer: establish it's really psychosis

Before antipsychotics, the vignette usually hands you the differential hooks: substance-induced (cannabis, stimulants, intoxication/withdrawal), medication effect, medical causes (delirium, thyroid, autoimmune, neurosyphilis/HIV screening), and mood episodes with psychotic features. If the stem includes fluctuating consciousness → delirium; if it gives mood congruence and course → psychotic depression or mania rather than a primary psychotic disorder. Step 2 rewards excluding these first.

Also capture duration of untreated psychosis (DUP) — the RAISE and other early-psychosis studies established that shorter DUP predicts better functional outcomes, which is why rapid initiation of an early-intervention-team referral is itself a high-yield move.

Step 2: start a second-generation antipsychotic

The consensus first-line for a first episode: a second-generation (atypical) antipsychotic — vignettes most often use risperidone or aripiprazole — initiated at a low dose and titrated upward as tolerated. First-episode patients are markedly more sensitive to both efficacy and side effects: drug-naïve brains respond at roughly half the usual dose, so starting low and going slow reduces dystonia, sedation and metabolic hit.

Practical points the questions test:

  • Consent and shared decision-making where capacity exists; involve family/caregivers with the patient's permission (family intervention reduces relapse).
  • Screen before/at initiation: personal/family cardiac history (QTc), metabolic baseline (weight, glucose, lipids), prolactin-relevant history, movement baseline (AIMS where indicated).
  • AIMS and metabolic monitoring on an ongoing schedule — the "start the antipsychotic AND order the monitoring" pairing is classic Step 2.

Step 3: continue after remission — the trap

Relapse after a first episode is the rule rather than the exception without maintenance treatment; guideline concordance is continued antipsychotic treatment for at least 12 months after a first episode (longer after multiple episodes), with the same agent that worked. The vignette's most reliable wrong answer: "she's improved — taper and stop the medication." Correct: continue maintenance, address adherence proactively (psychoeducation, side-effect management, formulation choices), and plan a slow cross-taper only if switching is genuinely indicated.

Step 4: the psychosocial package

Medication is only the pharmacological half. High-yield adjuncts:

  • Cognitive behavioural therapy for psychosis (CBTp) — recommended across guidelines for persistent symptoms and distress
  • Family psychoeducation and intervention — reduces relapse rates
  • Assertive community / early-intervention team involvement — the RAISE model: coordinated specialty care covering employment, education and case management
  • Substance-use treatment — cannabis and stimulant use predicts relapse; asking about it is markable

Answer-pattern table: key vs distractors

Clinical questionHigh-yield answerTypical distractor
Initial drug choiceSecond-generation antipsychotic, low starting doseHaloperidol high-dose; benzodiazepines alone
After 4 weeks, she's wellContinue maintenance ≥12 months + monitoringStop the antipsychotic
Which agent avoids metabolic burden?Aripiprazole/cariprazine-type profile favoured when metabolic risk is highOlanzapine as first choice in a young obese patient
Add-on for persistent symptomsCBTp + family intervention + supported education/employmentAdd a second antipsychotic immediately
Treatment resistance after trialsConsider clozapine per criteria — never first lineClozapine upfront for a first episode

Exam trap

Three reliable traps: (1) "feels better → stop medication" — always wrong; maintenance continues. (2) Jumping to clozapine — reserved for treatment resistance, never a first-episode first-line answer. (3) Forgetting monitoring — every antipsychotic-start vignette also wants metabolic labs and movement surveillance. If the patient is a young woman with high prolactin risk, expect a question hinting at aripiprazole's prolactin-sparing profile.

Monitoring, adherence and special situations

From initiation, monitoring is part of the answer, not an optional extra:

  • Metabolic: weight/BMI and waist circumference, fasting glucose or HbA1c, and lipid profile at baseline, then at 12 weeks and at least annually — more often if the agent and clinical picture warrant it.
  • Movement: baseline assessment and periodic AIMS examination; ask about acute dystonia and akathisia early, because these side effects in a frightened first-episode patient are the fastest route to discontinuation and relapse.
  • Prolactin and cardiac: symptom-driven prolactin checks (galactorrhoea, sexual dysfunction) and ECG where personal/family cardiac history or QTc-risk agents apply.

Adherence deserves deliberate strategy. First-episode patients frequently stop medication once distress resolves — not from defiance but from recovered self-narrative ("I was unwell, I'm fine now") plus side-effect burden. The evidence-based responses: shared decision-making about which agent's side-effect profile the patient tolerates best, family psychoeducation to carry the long-term rationale, explicit discussion of the relapse arithmetic after discontinuation, and long-acting injectable options considered when oral adherence has already failed repeatedly rather than as a default.

Special populations adjust the frame: adolescents and young adults have heightened sensitivity to antidepressant activation and metabolic effects; perinatal presentations route through obstetric coordination (including lactation-compatible agents); and older adults with late-life psychosis start lower and slower still, with a mandated search for neurodegenerative and medical causes before any primary-disorder label.

Finally, expect the differential to be revisited rather than settled at visit one. If symptoms persist despite adequate exposure and adherence, the case design reopens: substance review, autoimmune and neurodegenerative screens where age and presentation suggest, and only then the treatment-resistance pathway — with clozapine considered strictly on its own criteria rather than as an early escalation.

Prognostic framing belongs early too: outcome in first-episode psychosis tracks strongly with duration of untreated psychosis, substance use, family expressed emotion and adherence — all modifiable. Saying that out loud to a newly diagnosed patient converts a frightening label into a set of levers the treatment team actually pulls.

Frequently asked questions

What is the first-line treatment for first-episode psychosis on Step 2?

A second-generation antipsychotic (typically risperidone or aripiprazole in vignettes) started at a low dose and titrated up, combined with family involvement, early-intervention team referral and metabolic/movement monitoring. Rule out substance-induced and medical causes before committing to maintenance treatment.

Do you continue antipsychotics after the first episode resolves?

Yes. Guidelines recommend continuing the effective antipsychotic for at least 12 months after a first episode, with relapse risk high after discontinuation. Adherence support and shared decision-making are part of the answer; stopping after remission is the exam's favourite wrong option.

Why start at a low dose in first-episode psychosis?

Antipsychotic-naïve patients show greater sensitivity to both therapeutic and adverse effects — lower doses often suffice for response while reducing acute dystonia, sedation and orthostatic effects. Starting low and titrating slowly improves tolerability and, with it, engagement and long-term adherence.

What psychosocial treatments are required alongside medication?

Family psychoeducation and intervention, cognitive behavioural therapy for psychosis for persistent symptoms, substance-use treatment where relevant, and coordinated specialty care covering work and education (the RAISE model). Antipsychotics alone underperform the combined package in early-psychosis outcomes research.

Key takeaways

  • Exclude substance-induced and medical causes first; then start a second-generation antipsychotic low and slow.
  • Continue maintenance ≥12 months after a first episode — improvement is not a stop signal.
  • Monitor from day one: metabolic labs, weight, movement screening (AIMS).
  • Psychosocial package is half the answer: family intervention, CBTp, early-intervention team, dual-diagnosis work.
  • Relapse prevention and adherence support trump dose escalation; clozapine is never first-line here.

Build the full psychosis curriculum — pharmacology, guidelines and vignette drills — in Preppsy's USMLE Step 2 psychiatry pathway.

Cover image: “First-Episode Psychosis (cover)” by Preppsy Editorial Team (Original artwork) via Preppsy.